Chargement en cours...
Brodalumab for the treatment of moderate-to-severe psoriasis: case series and literature review
Brodalumab, a recombinant fully human monoclonal immunoglobulin IgG2 antibody with high affinity to human interleukin (IL)-17RA, is approved for the treatment of moderate-to-severe plaque psoriasis. In controlled clinical trials, brodalumab 210 mg administered by subcutaneous injection at weeks 0, 1...
Enregistré dans:
| Publié dans: | Clin Cosmet Investig Dermatol |
|---|---|
| Auteurs principaux: | , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Dove
2019
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6628099/ https://ncbi.nlm.nih.gov/pubmed/31372022 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CCID.S211938 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|